Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD
Information source: Shaheed Beheshti Medical University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Neovascular Age-Related Macular Degeneration
Intervention: bevacizumab, triamcinolone acetonide (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: Shaheed Beheshti Medical University Official(s) and/or principal investigator(s):
Hamid Ahmadieh, MD, Principal Investigator, Affiliation: Ophthalmic Research Center of Shaheed Beheshti Medical University
Summary
To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab
+ triamcinolone acetonide in neovascular AMD.
Clinical Details
Study design: Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: visual acuity
Secondary outcome: central macular thicknessleakage in fluorescein angiography intraocular pressure anterior chamber reaction
Eligibility
Minimum age: 50 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Cases of active neovascular AMD with visual acuity of 20/400- 20/40
Exclusion Criteria:
- History of glaucoma or ocular hypertension
- Disciform scar
Locations and Contacts
Hamid Ahmadieh, MD, Tehran 16666, Iran, Islamic Republic of
Additional Information
Starting date: November 2005
Last updated: November 13, 2006
|
